Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
November 15 2022 - 9:24AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
November 15,
2022
________________
NOVO NORDISK A/S
(Exact name of
Registrant as specified in its charter)
Novo Allé
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under cover
of Form 20-F or Form 40-F
Form 20-F [X] |
Form 40-F [ ] |
Indicate by check mark whether the registrant by furnishing the information contained in this
Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
If “Yes” is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g-32(b):82-________
Trading
in Novo Nordisk shares by board members, executives and associated persons
Bagsværd,
Denmark, 15 November 2022 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by
the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on
market abuse.
The company’s
board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in
Novo Nordisk shares by the company’s board members, executives and their associated persons.
Please
find below a statement of such trading in shares issued by Novo Nordisk.
1 |
Details
of the person discharging managerial responsibilities/person closely associated |
a) |
Name of the Board member/Executive/Associated
Person |
Andreas Fibig |
2 |
Reason
for the notification |
a) |
Position/status |
Member of the Board of Directors |
b) |
Initial notification/Amendment |
Initial notification |
3 |
Details
of the issuer |
a) |
Name |
Novo Nordisk A/S |
b) |
LEI |
549300DAQ1CVT6CXN342 |
4 |
Details
of the transaction(s) |
a) |
Description of the financial instrument, type of
instrument, |
ADRs |
Identification code |
NVO |
b) |
Nature of the transaction |
Purchase of ADRs |
Page 2 of 2
c) |
Price(s) and
volume(s) |
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
DKK 800.39 |
180 ADRs |
|
|
|
|
DKK 800.75 |
0.31 ADRs |
|
|
|
|
|
|
|
d) |
Aggregated information
·
Aggregated volume
·
Price |
180.31 ADRs
DKK 800.39
|
e) |
Date of the transaction |
2022-11-11 |
f) |
Place of the transaction |
Nasdaq New York Stock
Exchange |
Novo Nordisk is a leading global healthcare company, founded in
1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity
and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working
to prevent and ultimately cure disease. Novo Nordisk employs about 50,800 people in 80 countries and markets its products in around 170
countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO).
For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn and YouTube.
Contact for further information
Media: |
|
Ambre Brown Morley
+45 3079 9289
abmo@novonordisk.com |
Natalia Salomao Abrahao (US)
+1 848 304 1027
niaa@novonordisk.com |
|
|
Investors: |
|
Daniel Muusmann Bohsen
+45 3075 2175
dabo@novonordisk.com |
Jacob Martin Wiborg Rode
+45 3075 5956
jrde@novonordisk.com |
|
|
David Heiberg Landsted
+45 3077 6915
dhel@novonordisk.com |
Mark Joseph Root (US)
+1 848 213 3219
mjhr@novonordisk.com |
Novo Nordisk A/S
Investor Relations |
Novo Allé
2880 Bagsværd
Denmark |
Telephone:
+45 4444 8888 |
Internet: www.novonordisk.com CVR
no:
24 25 67 90 |
|
|
Company announcement No 85/ 2022 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly
caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
Date: November 15, 2022 |
NOVO NORDISK A/S
Lars Fruergaard Jørgensen
Chief Executive Officer |
Novo Nordisk (PK) (USOTC:NONOF)
Historical Stock Chart
From Sep 2024 to Oct 2024
Novo Nordisk (PK) (USOTC:NONOF)
Historical Stock Chart
From Oct 2023 to Oct 2024